Aug 21, 2026 Back Topline Data from Phase 2__b Studies Inform HBV F__unctional C__ure S__trategy_;_ Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC…
Aug 21, 2026
Back
Topline Data from Phase 2__b Studies Inform HBV F__unctional C__ure S__trategy_;_ Additional Data Expected in 2H 2026
Emerging Discovery Programs Build Momentum
BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC
Strong Cash Position Support__s Continued Strategic Execution

DURHAM, N.C. - Aug 20, 2026 / BEIJING, China – Aug 21, 2026 – Brii Biosciences Limited
(“Brii Bio,” or the “Company,” stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the six-month period ended June 30, 2026.
In the first half of 2026, Brii Bio generated additional clinical data supporting its differentiated hepatitis B virus (HBV) functional cure strategy while continuing to expand its internal discovery capabilities and advance its RNA-based technology platforms.
In its HBV clinical program, the Company presented end-of-study data from its Phase 2 ENSURE study at the European Association for the Study of the Liver (EASL) Congress 2026. On July 3, the Company also announced topline end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies. To date, findings across the ENSURE, ENRICH and ENHANCE studies have consistently supported the potential of BRII-179 to improve functional cure outcomes as part of a combination regimen. Detailed data from the ENRICH and ENHANCE studies are expected to be presented in the second half of 2026.
Beyond its HBV portfolio, the Company continued to advance its internal discovery capabilities and invest in the development of RNA-based technology platforms. Subsequent to the reporting period, the first participant was dosed in a clinical study evaluating BRII-5395, an internally discovered mRNA therapeutic vaccine for advanced hepatocellular carcinoma (HCC). This milestone represents the first clinical evaluation of an RNA-based therapeutic originating from Brii Bio’s internal discovery efforts. While BRII-5395 is an mRNA therapeutic vaccine, the Company’s broader RNA platforms encompass multiple RNA modalities. During the first half of 2026, Brii Bio progressed multiple internally discovered candidates across various stages of discovery and preclinical development, including programs that extend the application of its technology platforms into additional therapeutic areas beyond infectious diseases.
With effective cost control measures and optimized operating structure in place, Brii Bio remains well-capitalized, with a cash position of approximately US$260 million as of June 30, 2026, providing financial flexibility to support its late-stage HBV programs and early discovery initiatives.
“Our progress in the first half of the year reflects meaningful advances across both our late-stage HBV portfolio and our expanding discovery capabilities,” said Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio. “Data generated across our HBV studies continue to inform our functional cure strategy. At the same time, the initiation of clinical evaluation for BRII-5395 demonstrates our ability to translate internal discovery into pipeline assets. We look forward to sharing additional milestones later this year. Together, these efforts are building a more diversified pipeline and strengthening the foundation for sustainable innovation and long-term value creation.”
Corporate and Clinical Updates
HBV Program
Brii Bio continued to advance its HBV pipeline with a focus on achieving higher functional cure rates through novel combination regimens. The Company’s differentiated HBV portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic, and elebsiran, an HBV-targeting siRNA, has generated a growing body of clinical data supporting Brii Bio’s functional cure strategy through the completed Phase 2b ENSURE study and ongoing ENRICH and ENHANCE Phase 2b studies.
-
The Phase 2b ENSURE study was designed to assess the safety and efficacy of combination approaches aimed at improving functional cure outcomes. Cohorts 1-3 evaluated elebsiran in combination with PEG-IFNα compared to PEG-IFNα monotherapy. Cohort 4 evaluated the potential role of BRII-179 in enhancing immune responsiveness and improving hepatitis B surface antigen (HBsAg) loss rates. In the first half of 2026, end-of-study data from Cohorts 1-4 of the Phase 2 ENSURE study were presented at EASL 2026, demonstrating that:
- The HBsAg loss benefit observed in the elebsiran and PEG-IFNα combination cohorts resulted in a higher functional cure rate compared to the PEG-IFNα alone cohort.
- BRII-179-experienced participants achieved higher functional cure rates, particularly among anti-HBs responders, suggesting that BRII-179 may play an important role in achieving durable immunological control of HBV.
-
To further define the role of BRII-179 in HBV treatment and identify an optimal combination regimen for potential registrational development, the Company is evaluating BRII-179 in two additional ongoing Phase 2b studies: ENRICH and ENHANCE studies.
The ENRICH study evaluates BRII-179 as a priming therapy administered prior to elebsiran and PEG-IFNα treatment. The ENHANCE study evaluates a concurrent triple combination regimen of BRII-179, elebsiran, and PEG-IFNα to enhance the functional cure rates. In July, the Company announced topline end-of-treatment data from its Phase 2b ENRICH and ENHANCE studies.
- At EOT, the ENRICH study evaluating pre-treatment with BRII-179 followed by elebsiran and PEG-IFNα achieved HBsAg loss rates of 42.9% (42/98) and 40.0% (20/50) across two BRII-179 dosing schedules (five doses administered every 3 weeks and 7 doses administered every 2 weeks, respectively). These results were consistent with the 41.9% (13/31) HBsAg loss rate observed in ENSURE Cohort 4 among patients previously treated with BRII-179, supporting the potential immune-priming role of BRII-179.
- Subgroup analyses from the ENRICH study suggest potential differentiation in subjects with higher baseline HBsAg levels (1000-3000 IU/mL) comparing with other HBV functional cure regimens under development by other companies, consistent with prior findings from ENSURE Cohort 4, indicating that BRII-179 may induce beneficial immune responses regardless of baseline HBsAg levels in this difficult-to-treat population.
- At EOT, the ENHANCE (Part A-1) study evaluating a concurrent triple combination did not demonstrate improved HBsAg loss rates compared with ENSURE Cohorts 2 and 3, 29.7% (11/37), with an observed rate of 25.5% (25/98). Higher HBsAg loss rates, however, were observed compared with the PEG-IFNα control arm, 10.2% (5/49).
- The ENHANCE study also evaluated a sequential approach designed to potentially shorten PEG-IFNα therapy in its Part A-2 by administering BRII-179 plus elebsiran during the first 24 weeks followed by 24 weeks of elebsiran and PEG-IFNα. At EOT, this combination regimen achieved an HBsAg loss rate of 22.5% (18/80), suggesting that a full course of PEG-IFNα therapy may be important for achieving optimal functional cure outcomes.
No new safety concerns have been identified across ENSURE, ENRICH and ENHANCE to date.
On August 19, 2026, the Company received an email notification from one of its central laboratory service providers of a product recall involving a commercial assay kit1 used for HBsAg testing in the ENHANCE study. Based on the information currently available and the Company’s preliminary assessment, the potential impact on the clinical data of the Company’s sponsored trials publicly disclosed to date appears limited to the EOT HBsAg data for Part A-2 of the ENHANCE study. The Company is working with the service provider to identify potentially affected samples and arrange retesting using unaffected assay kits. Subject to completion of the retesting and further analysis, as at the date of this announcement, the Company has not identified any indication at this stage that the matter would materially affect its overall interpretation of the study results or the program development decisions announced to date. The Company will continue to evaluate the matter and provide updates as appropriate if any material developments arises.
The Company plans to present detailed data from the ENRICH and ENHANCE studies, including additional efficacy, safety and subgroup analyses, at a scientific conference in the second half of 2026.
Discovery Program Update
Brii Bio is expanding its RNA platforms beyond infectious diseases into new therapeutic areas. In the first half of 2026, the Company progressed multiple early-stage candidates spanning various stages of discovery and pre-clinical development, with a focus on generating differentiated therapeutic opportunities in diseases with significant unmet medical needs.
-
BRII-5395 is a novel mRNA therapeutic vaccine internally developed by Brii Bio. It is being evaluated as part of a combination immunotherapy approach for HBV-related HCC.
- On August 12, 2026, subsequent to the reporting period, the first participant was dosed in a clinical study evaluating BRII-5395 in participants with advanced HCC. The study, conducted at the Cancer Hospital of the Chinese Academy of Medical Sciences, is designed to evaluate the safety, tolerability, immunogenicity and preliminary anti-tumor activity of BRII-5395 in combination with an anti-PD-1 antibody and an anti-VEGF antibody. Current standard of care of immune checkpoint inhibitors have limited efficacy against HCC.
- As the first internally developed mRNA-based cancer therapeutic vaccine from Brii Bio to enter clinical evaluation, BRII-5395 represents an important milestone in the advancement of the Company’s internal discovery capabilities and RNA-based technology platforms.
While BRII-5395 is an mRNA therapeutic vaccine, the Company’s broader RNA platforms encompass multiple RNA modalities. In addition, the Company has extended the application of its technology platforms into additional therapeutic areas beyond infectious diseases.
Further program updates are expected throughout the remainder of 2026. The Company is actively exploring partnership opportunities to advance selected discovery programs to maximize the value of its emerging pipeline.
Additional Clinical Programs
- Brii Bio is actively seeking strategic partnerships for long-acting anti-HIV and multidrug resistant (MDR) antibacterial therapeutic candidates to maximize the development and commercialization potential.
Other Corporate Updates
On April 16, 2026, the Company and Brii Biosciences Offshore Limited, a subsidiary of the Company, submitted a Demand for Arbitration to the United States-based Judicial Arbitration and Mediation Services, Inc. against Vir Biotechnology, Inc. (the “Arbitration”).
The Company announced the commencement of the Arbitration on April 16, 2026 and provided a further update on May 22, 2026. As of June 30, 2026, the Arbitration remained in its early stages, and the parties had not reached a resolution of the claims.
In light of the ongoing arbitration, the Company is not currently advancing elebsiran into Phase 3 development and future development plans for elebsiran remain under evaluation pending resolution of the Arbitration. The Company will continue to monitor developments and update shareholders as appropriate.
Outlook
Looking ahead, the Company remains focused on advancing its differentiated HBV portfolio while continuing to progress its RNA-based discovery efforts.
The Company plans to continue investing in its internal discovery capabilities and RNA platforms to support the advancement of future pipeline candidates. Through these efforts, Brii Bio aims to generate new therapeutic opportunities and build a sustainable pipeline of innovative medicines addressing diseases with significant unmet medical needs.
With a strong balance sheet and disciplined execution, Brii Bio is well positioned to pursue value-creating opportunities and deliver on its strategic priorities.
Interim 2026 Financial Results
- The Company maintains a strong cash position to support its operations through 2029. Our bank deposits and cash and cash equivalents were RMB1,770.8 million as of June 30, 2026, representing a decrease of RMB170.2 million or 8.8% compared with RMB1,941.0 million as of December 31, 2025. The decrease was primarily due to payout of research and development activities and daily operations.
- Through pipeline prioritization, resource optimization, internalization of certain clinical development activities, and cost-saving measures of third-party vendors, we have effectively controlled our operational expenses. Research and development expenses were RMB98.3 million for the six months ended June 30, 2026, representing a decrease of RMB18.7 million or 16.0%, compared with RMB117.0 million for the six months ended June 30, 2025. The decrease was primarily attributable to organizational optimization, compensation framework adjustments, and lower third-party contracting costs as Phase 2 study activities for the HBV programs wound down, partially offset by increased investment in early-stage discovery.
- Administrative expenses were RMB52.6 million for the six months ended June 30, 2026, representing a decrease of RMB5.6 million or 9.6%, compared with RMB58.2 million for the six months ended June 30, 2025. The decrease primarily reflected lower employee costs following organizational optimization and adjustments to the senior management compensation framework, partially offset by the increase in professional fees and the depreciation and amortization cost.
- Other income was RMB19.5 million for the six months ended June 30, 2026, representing a decrease of RMB8.6 million or 30.6%, compared with RMB28.1 million for the six months ended June 30, 2025. This was mainly due to the decrease in bank interest income of RMB7.9 million attributable to the declining interest rates on time deposits.
Conference Call Information
The Company will host a live conference call in Chinese on August 21 at 8:30 a.m. HKT (8:30 p.m. ET on August 20). For the registration link, please click here
.
All participants shall use the link provided above to complete the online registration process prior to the conference call. A replay of the conference call will be available after the call and can be accessed by visiting the Company’s website at www.briibio.com
under the Investor Relations section.
This press release contains references to third-party information. Such information is not deemed to be incorporated by reference in this press release. Brii Bio disclaims responsibility for such third-party information.
About Brii Bio
Brii Biosciences Limited (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to improve patients’ health by addressing high unmet medical needs with limited treatment options. The Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in both China and the United States. For more information, visit www.briibio.com.
Forward-Looking Statement
The information communicated in this press release contains certain statements that are or may be forward-looking. These statements typically contain words such as “will,” “expects,” “believes,” “plans” and “anticipates,” and words of similar import. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There may be additional material risks that are currently not considered to be material or of which the Company is unaware. These forward-looking statements are not a guarantee of future performance. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
Media Inquiries:
[email protected]
Investor Inquiries:
[email protected]
Partnering Inquiries:
[email protected]
---------------------------------
1The relevant kit is Roche Elecsys HBsAg II quant II. For details of the product recall, please see the public recall announcement: https://qxzh.yjj.sh.gov.cn/openApi/recallDetail?recall.recallId=525e2adbd3454202bdc748ad47efb17a
Previous
Next 



[email protected]
[
](mailto: [email protected])
-
Home
-
Company
-
Science
-
Media
-
Back
-
Press Release
-
Back
-
Brii Biosciences Announces Upcoming Conference Participation in November
-
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
-
Brii Biosciences to Present New Phase 1 Data from HIV Program at IDWeek 2022
-
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression
-
Brii Biosciences Announces China Leadership Team Changes
-
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
-
Brii Biosciences Announces Upcoming Conference Participation in September
-
Brii Biosciences Provides Corporate Update and Reports 2022 Interim Results
-
WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics
-
Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
-
FierceBiotech names Brii Biosciences as one of its “Fierce 15” Biotech Companies of 2018
-
Brii Biosciences Launches to Bring Innovative Medicines to Chinese Patients
-
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
-
Brii Biosciences Expands Infectious Disease Pipeline
-
Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
-
Brii Biosciences Provides Corporate Update on Progress Against Strategic R&D Priorities
-
Brii Biosciences Appoints Rogers Luo, Ankang Li To Leadership Positions
-
Tsinghua University, 3rd People’s Hospital of Shenzhen and Brii Biosciences Establish Partnership to Develop Neutralizing Antibodies Against COVID-19
-
Brii Biosciences Provides Funding to Columbia University for Research on COVID-19 and Other Coronaviruses
-
Brii Biosciences Antibody Combination Will Not Progress into a Phase 3 Study Evaluating the Treatment of SARS-CoV-2 in Hospitalized Patients
-
Brii Biosciences Closes US$155 Million Series C Financing
-
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
-
Brii Biosciences Monoclonal Antibodies, BRII-196 and BRII-198, Progress to Phase 3 in NIH ACTIV-2 Trial in Ambulatory COVID-19 Patients
-
Brii Biosciences Provides Update on Strategic Clinical Development Progress
-
Brii Biosciences to Present Updated Phase 1b/2a Data on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
-
Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021
-
Brii Biosciences Limited Successfully Listed on Main Board of Hong Kong Stock Exchange
-
Brii Biosciences Initiates Phase 2 Clinical Trial in China for Neutralizing Antibodies, BRII-196 and BRII-198, in SARS-CoV-2
-
Brii Biosciences Announces the Completion of Enrollment in the Phase 3 National Institutes of Health (NIH) ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19
-
Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients
-
Brii Biosciences Adds US$100 Million to Advance its Late-Stage Monoclonal Antibody Combination Therapy, BRII-196/BRII-198, for Non-Hospitalized COVID-19 Patients
-
Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy
-
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression to Severe Disease
-
Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company’s SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021
-
Brii Biosciences Announces Upcoming Participation at November Conferences
-
Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit
-
Brii Biosciences Joins Hang Seng Composite Index
-
Brii Biosciences Included in Hong Kong Stock Connect
-
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China
-
Brii Biosciences Receives Clinical Hold Notification from US. FDA on BRII-732
-
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant
-
Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B
-
Brii Biosciences Appoints Eleanor de Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head
-
Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants
-
Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group to Advance the Commercialization of Long-acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
-
Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer
-
Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China
-
Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
-
Brii Biosciences Announces Upcoming Conference Participation in July
-
Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
-
Brii Bio Announces GMP Compliance Inspection Result for the Amubarvimab Injection and Romlusevimab Injection
-
Brii Biosciences Announces Upcoming Conference Participation in June
-
Brii Biosciences to be Added to MSCI China Small Cap Index
-
Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
-
Brii Bio Reports Progress on ESG Commitments in Its Inaugural ESG Report
-
Brii Biosciences Announces Upcoming Participation at May Conference
-
Brii Biosciences Announces Upcoming Participation at April Conferences
-
Brii Bio Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
-
Brii Bio Announces Strategic Partnership with Sinopharm to Advance Commercialization of Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
-
Brii Biosciences Provides Corporate Update and Reports Full Year 2021 Financial Results
-
Brii Bio to Present Phase 2 Data on Two Monthly Doses of BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022
-
Brii Bio Announces that National Health Commission of China Adds Amubarvimab/Romlusevimab Combination to its COVID-19 Diagnosis and Treatment Guidelines (9th Pilot Edition)
-
Brii Biosciences Announces Upcoming Participation at March Conferences
-
Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources
-
Brii Biosciences Announces Upcoming Conference Participation in January
-
Brii Biosciences Provides Update on Strategic Clinical Development Progress
-
Brii Biosciences Announces Interim Results from Phase 2 Study Evaluating Combination BRII-835 and BRII-179 in Development for HBV Functional Cure
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Press Release
-
Media Reports
-
Investor Relations
-
People
-
Contact Us
© 2026 Brii Biosciences. All Rights Reserved.
| Developed by Euroland IR
Recruitment Scam Warning
Privacy Statement
Terms of Use
This website uses cookies and similar technologies, to enhance your browsing experience and provide personalized recommendations. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our Privacy Policy
Accept